Stocks · News reference
NeOnc Technologies Holdings, Inc. announced its financial results for the third quarter ended September 30, 2026, alongside updates on its clinical development programs.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-05 AccNo: 0001829126-26-012024 Size: 239 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
NeOnc Technologies Holdings, Inc. submitted its quarterly financial report (Form 10-Q) to the SEC for the period ending September 30, 2026.
NeOnc Technologies Holdings (NASDAQ: NTHI), a clinical-stage biopharmaceutical company, will present data from two investigational brain cancer programs—intranasal NEO100 and oral NEO212—at the Society for Neuro-Oncology annual meeting on November 13, 2026. The company is advancing ambitious plans for a 500-patient international clinical trial across 30 hospitals in three countries, leveraging innovative drug delivery approaches and AI-assisted tumor modeling technology.
NeOnc Technologies Holdings, Inc. announced it will present updated clinical data for its intranasal NEO100 and oral NEO212 programs at the 31st Annual Meeting of the Society for Neuro-Oncology.
NeOnc Technologies Holdings is planning a significant expansion of its clinical research with a proposed trial targeting approximately 500 patients across 30 hospitals in three countries.